Literature DB >> 30383447

Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.

Michael A Brehm1, Laurie L Kenney1, Michael V Wiles2, Benjamin E Low2, Roland M Tisch3, Lisa Burzenski2, Christian Mueller4, Dale L Greiner1, Leonard D Shultz2.   

Abstract

Immunodeficient mice engrafted with human peripheral blood mononuclear cells (PBMCs) support preclinical studies of human pathogens, allograft rejection, and human T-cell function. However, a major limitation of PBMC engraftment is development of acute xenogeneic graft- versus-host disease (GVHD) due to human T-cell recognition of murine major histocompatibility complex (MHC). To address this, we created 2 NOD- scid IL-2 receptor subunit γ ( IL2rg) null (NSG) strains that lack murine MHC class I and II [NSG-β-2-microglobulin ( B2M) null ( IA IE)null and NSG -( Kb Db) null ( IAnull)]. We observed rapid human IgG clearance in NSG- B2Mnull ( IA IE) null mice whereas clearance in NSG -( Kb Db) null ( IAnull) mice and NSG mice was comparable. Injection of human PBMCs into both strains enabled long-term engraftment of human CD4+ and CD8+ T cells without acute GVHD. Engrafted human T-cell function was documented by rejection of human islet allografts. Administration of human IL-2 to NSG -( Kb Db) null ( IAnull) mice via adeno-associated virus vector increased human CD45+ cell engraftment, including an increase in human regulatory T cells. However, high IL-2 levels also induced the development of GVHD. These data document that NSG mice deficient in murine MHC support studies of human immunity in the absence of acute GVHD and enable evaluation of human antibody therapeutics targeting human T cells.-Brehm, M. A., Kenney, L. L., Wiles, M. V., Low, B. E., Tisch, R. M., Burzenski, L., Mueller, C., Greiner, D. L., Shultz, L. D. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.

Entities:  

Keywords:  GVHD; HU-PBL-SCID; humanized; immunodeficient

Mesh:

Year:  2018        PMID: 30383447      PMCID: PMC6404556          DOI: 10.1096/fj.201800636R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  55 in total

1.  Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical.

Authors:  Yi He; Marc S Weinberg; Matt Hirsch; Mark C Johnson; Roland Tisch; R Jude Samulski; Chengwen Li
Journal:  Hum Gene Ther       Date:  2013-05-02       Impact factor: 5.695

2.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.

Authors:  D M McCarty; P E Monahan; R J Samulski
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

3.  A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4+ or CD8+ T Cells Using Immunodeficient NOG Mice.

Authors:  R Ito; I Katano; K Kawai; M Yagoto; T Takahashi; Y Ka; T Ogura; R Takahashi; M Ito
Journal:  Am J Transplant       Date:  2016-12-21       Impact factor: 8.086

4.  Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.

Authors:  E J Wagar; M A Cromwell; L D Shultz; B A Woda; J L Sullivan; R M Hesselton; D L Greiner
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

5.  The earliest knockouts.

Authors:  Michael J Bevan
Journal:  J Immunol       Date:  2010-05-01       Impact factor: 5.422

6.  Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.

Authors:  Nadja Hilger; Jakob Glaser; Claudia Müller; Christoph Halbich; Anne Müller; Ulla Schwertassek; Jörg Lehmann; Peter Ruschpler; Franziska Lange; Andreas Boldt; Lilly Stahl; Ulrich Sack; Christopher Oelkrug; Frank Emmrich; Stephan Fricke
Journal:  Cytometry A       Date:  2016-08-25       Impact factor: 4.355

7.  Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary.

Authors:  Ramesh Akkina; Atef Allam; Alejandro B Balazs; Joel N Blankson; John C Burnett; Sofia Casares; J Victor Garcia; Kim J Hasenkrug; Fatah Kashanchi; Scott G Kitchen; Florian Klein; Priti Kumar; Andrew D Luster; Larisa Y Poluektova; Mangala Rao; Brigitte E Sanders-Beer; Leonard D Shultz; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02       Impact factor: 2.205

8.  Transfer of a functional human immune system to mice with severe combined immunodeficiency.

Authors:  D E Mosier; R J Gulizia; S M Baird; D B Wilson
Journal:  Nature       Date:  1988-09-15       Impact factor: 49.962

9.  Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.

Authors:  Niwa Ali; Barry Flutter; Robert Sanchez Rodriguez; Ehsan Sharif-Paghaleh; Linda D Barber; Giovanna Lombardi; Frank O Nestle
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

10.  Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.

Authors:  M A King; L Covassin; M A Brehm; W Racki; T Pearson; J Leif; J Laning; W Fodor; O Foreman; L Burzenski; T H Chase; B Gott; A A Rossini; R Bortell; L D Shultz; D L Greiner
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

View more
  32 in total

Review 1.  Understanding Normal and Malignant Human Hematopoiesis Using Next-Generation Humanized Mice.

Authors:  Yoriko Saito; Leonard D Shultz; Fumihiko Ishikawa
Journal:  Trends Immunol       Date:  2020-07-03       Impact factor: 16.687

Review 2.  Humanized mouse model: a review on preclinical applications for cancer immunotherapy.

Authors:  Ling Yin; Xue-Jing Wang; De-Xi Chen; Xiao-Ni Liu; Xiao-Jun Wang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  Humanized mouse models of immunological diseases and precision medicine.

Authors:  Leonard D Shultz; James Keck; Lisa Burzenski; Sonal Jangalwe; Shantashri Vaidya; Dale L Greiner; Michael A Brehm
Journal:  Mamm Genome       Date:  2019-03-07       Impact factor: 2.957

Review 4.  Humanized Mouse Models for Evaluation of PSC Immunogenicity.

Authors:  Jack Hermsen; Matthew E Brown
Journal:  Curr Protoc Stem Cell Biol       Date:  2020-09

Review 5.  The mouse resource at National Resource Center for Mutant Mice.

Authors:  Cunxiang Ju; Juan Liang; Mingkun Zhang; Jinlong Zhao; Ling'en Li; Shuai Chen; Jing Zhao; Xiang Gao
Journal:  Mamm Genome       Date:  2022-02-09       Impact factor: 2.957

Review 6.  The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents.

Authors:  Y Maurice Morillon; Ariana Sabzevari; Jeffrey Schlom; John W Greiner
Journal:  Anticancer Res       Date:  2020-10       Impact factor: 2.480

7.  Spectrum of Posttransplant Lymphoproliferations in NSG Mice and Their Association With EBV Infection After Engraftment of Pediatric Solid Tumors.

Authors:  Heather Tillman; Peter Vogel; Tiffani Rogers; Walter Akers; Jerold E Rehg
Journal:  Vet Pathol       Date:  2020-03-23       Impact factor: 2.221

Review 8.  Human iPS Cell-derived Tissue Engineered Vascular Graft: Recent Advances and Future Directions.

Authors:  Xiangyu Shi; Lile He; Shang-Min Zhang; Jiesi Luo
Journal:  Stem Cell Rev Rep       Date:  2020-11-23       Impact factor: 5.739

Review 9.  Humanized Mouse Models for the Study of Periodontitis: An Opportunity to Elucidate Unresolved Aspects of Its Immunopathogenesis and Analyze New Immunotherapeutic Strategies.

Authors:  Carolina Rojas; Michelle P García; Alan F Polanco; Luis González-Osuna; Alfredo Sierra-Cristancho; Samanta Melgar-Rodríguez; Emilio A Cafferata; Rolando Vernal
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

10.  A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy.

Authors:  Shengchao Xu; Xi Yan; Gan Dai; Chengke Luo
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.